Samuel Katz, MD, PhD
Cell Death Regulation by Pro-Apoptotic BOK in Multiple Myeloma
Although the chemotherapeutic bortezomib has dramatically improved the survival of myeloma patients, nearly everyone develops resistance. We identified that a protein called BOK, which is frequently deleted in cancer, coordinates multiple ways cells die in response to bortezomib. We aim to identify therapeutic targets to re-activate BOK-driven cell death pathways.